Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • PRESCRIPTION DRUGS—D.D.C.: IRA’s Drug Price Negotiation Program not unconstitutional, federal trial court holds
    • BILLING AND CODING—SETTLEMENT AGREEMENTS: In-home health provider will pay $2.4 million to settle Medicare Advantage false coding claim
    • CONDITIONS OF PARTICIPATION—DAB DECISIONS: Patient abuse and neglect conviction basis for 5-year exclusion, despite being ‘excessively harsh’ according to ALJ
    • CONTROLLED SUBSTANCES—FINAL RULES: DEA targets emerging kratom-derived opioids with Schedule I action
    • CONTROLLED SUBSTANCES—NOTICES: FDA seeks input on global drug controls
    • DRUGS AND BIOLOGICS—NOTICES: FDA clears path for generic Cabazitaxel
    • FALSE CLAIMS ACT—D. Mass.: Court grants in part motions to quash subpoenas of non-parties in qui tam action
    • GENERIC DRUGS—D.C. Cir.: Norwich wins partial appeal over rifaximin exclusivity dispute; court orders FDA reconsideration
    • HATCH WAXMAN ACT—D. Del.: Court rejects Vertex bid to expand ivacaftor patent scope
    • MEDICAID—GAO REPORTS: Millions of working adults, many employed by the nation’s largest companies, remain enrolled in Medicaid and SNAP
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, CONTROLLED SUBSTANCES—FINAL RULES: DEA targets emerging kratom-derived opioids with Schedule I action, (Aug 28, 2026)

    By WK Editorial Staff

    DEA temporarily placed three kratom-related synthetic opioids in Schedule I, citing serious overdose, addiction, and public safety concerns.

    The DEA issued a temporary order placing mitragynine pseudoindoxyl, MGM-15, and MGM-16, three synthetic substa ...

    By WK Editorial Staff

    DEA temporarily placed three kratom-related synthetic opioids in Schedule I, citing serious overdose, addiction, and public safety concerns.

    The DEA issued a temporary order placing mitragynine pseudoindoxyl, MGM-15, and MGM-16, three synthetic substances related to 7-hydroxymitragynine, in Schedule I of the Controlled Substances Act after finding that they pose an imminent hazard to public safety. The agency cited evidence that mitragynine pseudoindoxyl and MGM-15 are being marketed and sold nationwide in consumer products, often promoted as mood enhancers or alternatives to prescription opioids despite their potent opioid effects and lack of FDA-approved medical uses. DEA stated that the substances have high abuse potential, may cause dependence and respiratory depression, and have been identified in overdose and toxicology cases, including fatal events. The temporary scheduling order, effective August 26, 2026, imposes Schedule I regulatory controls and will remain in effect for up to two years while the agency considers permanent scheduling (Final Rule, 91 Fed. Reg. 54948 (Aug. 26, 2026)).

    Dates. This temporary order is effective August 26, 2026, until August 26, 2028. If this order is extended or made permanent, DEA will publish a document in the Federal Register.

    FederalRegisterIssuances: FinalRules ControlledNews DrugBiologicNews

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use